Yamo Pharmaceuticals

Executive Summary

Yamo Pharmaceuticals is a San Diego-based clinical-stage biotech focused on developing novel small molecule therapies for neurological disorders, with its lead program L1-79 targeting core social deficits in Autism Spectrum Disorder (ASD). By modulating catecholamine networks, L1-79 aims to address a significant unmet medical need in ASD, where approved treatments primarily address comorbid symptoms rather than core social impairments. The company is currently conducting Phase 2 trials to evaluate L1-79's efficacy and safety, leveraging a unique mechanism of action that could differentiate it from existing therapies. Despite being private and early-stage, Yamo's focused approach and the large addressable market for ASD treatments position it as a potential player in the neuropsychiatric space. Success in Phase 2 would represent a major milestone, potentially attracting partnership interest or further funding to support late-stage development.

Upcoming Catalysts (preview)

• Q2 2026Phase 2 Top-Line Data Readout for L1-79 in ASD40% success
• Q3 2026FDA Type C Meeting or Special Protocol Assessment Guidance30% success
• Q4 2026Strategic Partnership or Licensing Deal for L1-7920% success